GGrantIndex
Sort

48,018 grants matching immunotherapy

Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer

$572,168
Dan R Littman · New York University School Of Medicine · R01 · FY2021 · CA

Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer

$572,168
Dan R Littman · New York University School Of Medicine · R01 · FY2025 · CA

Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.

$572,160
Mary L. Disis · University Of Washington · R01 · FY2010 · CA

The use of chitosan for cancer vaccine delivery

$572,121
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Myeloid-lineage cells and immunopathology in Leishmania braziliensis

$572,099
Phillip A. Scott · University Of Pennsylvania · U01 · FY2014 · AI

Myeloid-lineage cells and immunopathology in Leishmania braziliensis

$572,098
Phillip A. Scott · University Of Pennsylvania · U01 · FY2015 · AI

Identifying Therapeutic Targets for Stage III Melanoma

$571,965
Anand K Ganesan · University Of California-Irvine · R01 · FY2022 · CA

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

$571,864
Deric L Wheeler · University Of Wisconsin-Madison · R01 · FY2024 · CA

Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation

$571,835
Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2025 · NS

Bioinformatic Tools for Interpretation of Glycan Array Data

$571,833
Jian Zhang · Z Biotech, Llc · R43 · FY2019 · GM

Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse

$571,813
Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · NS

Linking Synucleinopathy and Dysfunction of Olfactory Pathways

$571,807
Patrik Brundin · Van Andel Research Institute · R01 · FY2017 · DC

Engineering immunotherapeutic probiotics to mitigate irAE

$571,668
Tal Danino · Columbia Univ New York Morningside · U01 · FY2024 · CA

ANTIVIRAL &ANTIFIBROTIC LIVER THERAPY OF HCV+ DRINKERS

$571,650
Mount Sinai School Of Medicine Of Nyu · R01 · FY2004 · AA

3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation

$571,644
Joseph F Costello · University Of California, San Francisco · R01 · FY2021 · CA

Testing the role of BATF as a pioneer transcription factor in effector T cells

$571,546
William Nicholas Haining · Dana-Farber Cancer Inst · R01 · FY2016 · AI

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma

$571,523
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2023 · CA

Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer

$571,496
Jianmin Zhang · University Of Toledo Health Sci Campus · R01 · FY2024 · CA

Combating melanoma resistance by targeting ABL1/2

$571,489
Rina Plattner · University Of Kentucky · R01 · FY2023 · CA

Mucosal T cell memory to pathogens

$571,485
David Masopust · University Of Minnesota · R37 · FY2025 · AI

Mucosal T cell memory to pathogens

$571,485
David Masopust · University Of Minnesota · R37 · FY2024 · AI

Single Cell Methods for Bioeffector Discovery and Analysis

$571,471
Brian O Bachmann · Vanderbilt University · R01 · FY2022 · CA

Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer Immunotherapy

$571,456
Jun Wang · New York University School Of Medicine · R37 · FY2025 · CA

Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma

$571,444
Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2023 · CA

Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma

$571,444
Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2025 · CA